WCM
ADVM

Weld Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

Weld Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,258
Closed -$221K – 453
2020
Q1 		$221K Buy
+2,258
New +$263K 0.11% 291

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Weld Capital Management's ADVM Position: Q2 2020 in Review

Weld Capital Management sold out of Adverum Biotechnologies (ADVM) in Q2 2020, closing a stake of 2,258 shares — an estimated $221K sold.

Weld Capital Management first reported a position in ADVM in Q1 2020 and held it in 1 quarter. The position peaked at $221K in Q1 2020. 141 funds tracked by Wall St. Rank hold ADVM as of Q2 2020.

  • Weld Capital Management reported no remaining Adverum Biotechnologies position as of Q2 2020 after selling out during the quarter.
  • Weld Capital Management sold 2,258 Adverum Biotechnologies shares in Q2 2020, an estimated $221K.
  • Weld Capital Management first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 1 quarter.
  • Weld Capital Management's Adverum Biotechnologies position peaked at $221K in Q1 2020.
  • 141 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2020.

Based on Weld Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.